Literature DB >> 9828039

Modern drug development from traditional medicinal plants using radioligand receptor-binding assays.

R Misra1.   

Abstract

Traditional medicinal plants in various countries, particularly in India have been used for centuries for various ailments; however, there has been little scientific effort to validate these anecdotal uses mentioned in the literature. A number of these traditionally used plant extracts and various "Ayurvedic medicines" that are highly valued in Ayurveda, the traditional system of medicine in India for antiaging, memory-enhancing, nerve tonic, anxiolytic, anti-inflammatory and immunopotentiation, have been screened using National Institutes of Mental Health (NIMH) Synthetic Screening Program for scientific validation and the development of new leads of psychotherapeutic compounds using Radioligand Receptor Binding Assays (RRA). Crude methanolic extracts of plants are screened using approximately 40 different in vitro RRA (primarily from rat brain homogenates) and 6 enzyme assays including acetylcholine esterase, choline acetyltransferase, and monoamine oxidase (MAO), A and B. The total crude extracts of many of these plants showed potent selectivity to various receptors, especially gamma-Amino Butyric Acid (GABA(A)), N-Methyl-D-Aspartic Acid (NMDA), and MAO receptors, which are presumed to be involved in mental disorders. The focus was on plants showing the highest displacement of GABA, cholecystokinin (CCK), NMDA, MAO, and benzodiazopines. Bioassay guided fractionation of the most active extracts resulted in pure compounds which retained the original activity of the crude extract validating the folkloric use. A bioactivity-guided fractionation of Terminalia bellerica fruit extract led to the isolation of several pure compounds which retained the original activity of the crude extract for CCK and GABA receptors, with the exception of compound B3EA-6, which exhibited high affinity for Neurokinin receptor (Substance K approximately NK-1). The absolute structure of B3EA-6 has been established by x-ray crystallography.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9828039     DOI: 10.1002/(sici)1098-1128(199811)18:6<383::aid-med3>3.0.co;2-a

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  6 in total

Review 1.  Exploring biology with small organic molecules.

Authors:  Brent R Stockwell
Journal:  Nature       Date:  2004-12-16       Impact factor: 49.962

2.  Discovering active compounds from mixture of natural products by data mining approach.

Authors:  Yi Wang; Yecheng Jin; Chenguang Zhou; Haibin Qu; Yiyu Cheng
Journal:  Med Biol Eng Comput       Date:  2008-03-05       Impact factor: 2.602

3.  Extract from Terminalia chebula seeds protect against experimental ischemic neuronal damage via maintaining SODs and BDNF levels.

Authors:  Joon Ha Park; Han Seung Joo; Ki-Yeon Yoo; Bich Na Shin; In Hye Kim; Choong Hyun Lee; Jung Hoon Choi; Kyunghee Byun; Bonghee Lee; Soon Sung Lim; Myong Jo Kim; Moo-Ho Won
Journal:  Neurochem Res       Date:  2011-06-12       Impact factor: 3.996

4.  Complementary and alternative medicine use for treatment and prevention of late-life mood and cognitive disorders.

Authors:  Helen Lavretsky
Journal:  Aging health       Date:  2009-02-01

5.  Neuroprotective potential of phytochemicals.

Authors:  G Phani Kumar; Farhath Khanum
Journal:  Pharmacogn Rev       Date:  2012-07

Review 6.  Ethnopharmacological Approaches for Dementia Therapy and Significance of Natural Products and Herbal Drugs.

Authors:  Devesh Tewari; Adrian M Stankiewicz; Andrei Mocan; Archana N Sah; Nikolay T Tzvetkov; Lukasz Huminiecki; Jarosław O Horbańczuk; Atanas G Atanasov
Journal:  Front Aging Neurosci       Date:  2018-02-12       Impact factor: 5.750

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.